Aptinyx sinks as Phase II study of NYX-458 fails

28 February 2023

US CNS specialist Aptinyx (Nasdaq: APTX) saw its shares plunge more than 56% to $0.26, after it released Phase II clinical study results evaluating the effects of NYX-458 in patients with cognitive impairment associated with Parkinson’s disease and dementia with Lewy bodies.

Across the overall study population, NYX-458 did not demonstrate clinically-meaningful improvements over placebo on the study’s efficacy endpoints. The results do not support further development of NYX-458, Aptinyx admitted.

“We are very disappointed that the results of this Phase II study did not validate the therapeutic potential observed previously in pre-clinical studies of NYX-458 in models of cognitive impairment,” said Dr Andy Kidd, president and chief executive of Aptinyx.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK